Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism



Page Path
HOME > Search
4 "Eun Jin Han"
Article type
Publication year
Original Article
Clinical Study
The Relationship between 10-Year Cardiovascular Risk Calculated Using the Pooled Cohort Equation and the Severity of Non-Alcoholic Fatty Liver Disease
Jeong In Lee, Min Chul Kim, Byung Sub Moon, Young Seok Song, Eun Na Han, Hyo Sun Lee, Yoonjeong Son, Jihyun Kim, Eun Jin Han, Hye-Jeong Park, Se Eun Park, Cheol-Young Park, Won-Young Lee, Ki-Won Oh, Sung-Woo Park, Eun-Jung Rhee
Endocrinol Metab. 2016;31(1):86-92.   Published online March 16, 2016
  • 4,021 View
  • 39 Download
  • 22 Citations
AbstractAbstract PDFPubReader   CrossRef-TDMCrossref - TDM

We investigated the association between the severity of non-alcoholic fatty liver disease (NAFLD) and the estimated 10-year risk of cardiovascular disease (CVD) calculated by Pooled Cohort Equation (PCE) and Framingham risk score (FRS).


A total of 15,913 participants (mean age, 46.3 years) in a health screening program were selected for analysis. The presence and severity of fatty liver was assessed by abdominal ultrasonogram. Subjects who drank alcohol more than three times a week were excluded from the study.


Among the participants, 57.6% had no NAFLD, 35.4% had grade I, 6.5% had grade II, and 0.5% had grade III NAFLD. Mean estimated 10-year CVD risk was 2.59%, 3.93%, 4.68%, and 5.23% calculated using the PCE (P for trend <0.01) and 4.55%, 6.39%, 7.33%, and 7.13% calculated using FRS, according to NAFLD severity from none to severe (P for trend <0.01). The odds ratio for ≥7.5% estimated CVD risk calculated using the PCE showed a higher correlation with increasing severity of NAFLD even after adjustment for conventional CVD risk factors (1.52, 2.56, 3.35 vs. the no NAFLD group as a reference, P<0.01) compared with calculated risk using FRS (1.65, 1.62, 1.72 vs. no NAFLD group as a reference, P<0.01).


In our study of apparently healthy Korean adults, increasing severity of NAFLD showed a higher correlation with estimated 10-year CVD risk when calculated using the PCE than when calculated using FRS.


Citations to this article as recorded by  
  • Nonalcoholic Fatty Liver Disease Increases Cardiovascular Risk in Inflammatory Bowel Diseases
    Dana Kablawi, Faisal Aljohani, Chiara Saroli Palumbo, Sophie Restellini, Alain Bitton, Gary Wild, Waqqas Afif, Peter L Lakatos, Talat Bessissow, Giada Sebastiani
    Crohn's & Colitis 360.2023;[Epub]     CrossRef
  • Fatty Liver Disease: Diagnosis and Stratification
    Yedidya Saiman, Andres Duarte-Rojo, Mary E. Rinella
    Annual Review of Medicine.2022; 73(1): 529.     CrossRef
  • “Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV”
    Adriana Cervo, Giada Sebastiani, Jovana Milic, Thomas Krahn, Sergio Mazzola, Salvatore Petta, Antonio Cascio, Giovanni Guaraldi, Giovanni Mazzola
    HIV Medicine.2022; 23(8): 911.     CrossRef
  • Value of the triglyceride glucose index combined with body mass index in identifying non-alcoholic fatty liver disease in patients with type 2 diabetes
    Nong Li, Huiwen Tan, Aixia Xie, Cheng Li, Xuan Fu, Weiting Xang, Amina Kirim, Xuefang Huang
    BMC Endocrine Disorders.2022;[Epub]     CrossRef
  • The Relation Between Non-alcoholic Fatty Liver Disease and the Risk of Coronary Heart Disease
    Seyed Moayed Alavian, Hosein Zadi
    Multidisciplinary Cardiovascular Annals.2022;[Epub]     CrossRef
  • Risk factors for cardiovascular disease among individuals with hepatic steatosis
    Julia Karády, Maros Ferencik, Thomas Mayrhofer, Nandini M. Meyersohn, Daniel O. Bittner, Pedro V. Staziaki, Balint Szilveszter, Travis R. Hallett, Michael T. Lu, Stefan B. Puchner, Tracey G. Simon, Borek Foldyna, Geoffrey S. Ginsburg, Robert W. McGarrah,
    Hepatology Communications.2022; 6(12): 3406.     CrossRef
  • Triglyceride Glucose Index and Related Parameters (Triglyceride Glucose-Body Mass Index and Triglyceride Glucose-Waist Circumference) Identify Nonalcoholic Fatty Liver and Liver Fibrosis in Individuals with Overweight/Obesity
    Mohammad E. Khamseh, Mojtaba Malek, Rowshanak Abbasi, Hoda Taheri, Maryam Lahouti, Fariba Alaei-Shahmiri
    Metabolic Syndrome and Related Disorders.2021; 19(3): 167.     CrossRef
  • Interplay between non‐alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population
    Grazia Pennisi, Vito Di Marco, Carola Buscemi, Giovanni Mazzola, Cristiana Randazzo, Federica Spatola, Antonio Craxì, Silvio Buscemi, Salvatore Petta
    Journal of Gastroenterology and Hepatology.2021; 36(9): 2389.     CrossRef
  • Non-Laboratory-Based Simple Screening Model for Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Developed Using Multi-Center Cohorts
    Jiwon Kim, Minyoung Lee, Soo Yeon Kim, Ji-Hye Kim, Ji Sun Nam, Sung Wan Chun, Se Eun Park, Kwang Joon Kim, Yong-ho Lee, Joo Young Nam, Eun Seok Kang
    Endocrinology and Metabolism.2021; 36(4): 823.     CrossRef
  • Coronary Artery Disease is More Severe in Patients with Non-Alcoholic Steatohepatitis than Fatty Liver
    Toshihiro Niikura, Kento Imajo, Anna Ozaki, Takashi Kobayashi, Michihiro Iwaki, Yasushi Honda, Takaomi Kessoku, Yuji Ogawa, Masato Yoneda, Hiroyuki Kirikoshi, Satoru Saito, Atsushi Nakajima
    Diagnostics.2020; 10(3): 129.     CrossRef
  • Cardiovascular Disease in Nonalcoholic Steatohepatitis: Screening and Management
    Hersh Shroff, Lisa B. VanWagner
    Current Hepatology Reports.2020; 19(3): 315.     CrossRef
  • Triglyceride Glucose Index Is Superior to the Homeostasis Model Assessment of Insulin Resistance for Predicting Nonalcoholic Fatty Liver Disease in Korean Adults
    Sang Bae Lee, Min Kyung Kim, Shinae Kang, Kahui Park, Jung Hye Kim, Su Jung Baik, Ji Sun Nam, Chul Woo Ahn, Jong Suk Park
    Endocrinology and Metabolism.2019; 34(2): 179.     CrossRef
  • Mortality Risk Detected by Atherosclerotic Cardiovascular Disease Score in Patients With Nonalcoholic Fatty Liver Disease
    Pegah Golabi, Natsu Fukui, James Paik, Mehmet Sayiner, Alita Mishra, Zobair M. Younossi
    Hepatology Communications.2019; 3(8): 1050.     CrossRef
  • Lower hand grip strength in older adults with non-alcoholic fatty liver disease: a nationwide population-based study
    Beom-Jun Kim, Seong Hee Ahn, Seung Hun Lee, Seongbin Hong, Mark W. Hamrick, Carlos M. Isales, Jung-Min Koh
    Aging.2019; 11(13): 4547.     CrossRef
  • Implication of Nonalcoholic Fatty Liver Disease, Metabolic Syndrome, and Subclinical Inflammation on Mild Renal Insufficiency
    Ga Eun Nam, Soon Young Hwang, Hye Soo Chung, Ju Hee Choi, Hyun Jung Lee, Nam Hoon Kim, Hye Jin Yoo, Ji-A Seo, Sin Gon Kim, Nan Hee Kim, Sei Hyun Baik, Kyung Mook Choi
    International Journal of Endocrinology.2018; 2018: 1.     CrossRef
  • Implication of liver enzymes on incident cardiovascular diseases and mortality: A nationwide population-based cohort study
    Kyung Mook Choi, Kyungdo Han, Sanghyun Park, Hye Soo Chung, Nam Hoon Kim, Hye Jin Yoo, Ji-A Seo, Sin Gon Kim, Nan Hee Kim, Sei Hyun Baik, Yong Gyu Park, Seon Mee Kim
    Scientific Reports.2018;[Epub]     CrossRef
  • Controlled Attenuation Parameter as a Noninvasive Method to Detect and Quantify Hepatic Steatosis in Chronic Liver Disease: What Is the Clinical Relevance
    Mariana Verdelho Machado
    GE - Portuguese Journal of Gastroenterology.2017; 24(4): 157.     CrossRef
  • Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case-control study
    Gyuri Kim, Suk-Yong Jang, Eugene Han, Yong-ho Lee, Se-young Park, Chung Mo Nam, Eun Seok Kang
    International Journal of Cancer.2017; 140(4): 798.     CrossRef
  • Clinical Characteristics of Non-Alcoholic Fatty Liver Disease Based on Analyses from the Kangbuk Samsung Health Study
    Eun-Jung Rhee
    The Journal of Korean Diabetes.2017; 18(2): 81.     CrossRef
  • Increased risk for development of coronary artery calcification in subjects with non-alcoholic fatty liver disease and systemic inflammation
    Jihyun Kim, Da Young Lee, Se Eun Park, Cheol-Young Park, Won-Young Lee, Ki-Won Oh, Sung-Woo Park, Eun-Jung Rhee, Susanne Kaser
    PLOS ONE.2017; 12(7): e0180118.     CrossRef
  • Articles inEndocrinology and Metabolismin 2016
    Won-Young Lee
    Endocrinology and Metabolism.2017; 32(1): 62.     CrossRef
  • Non-Alcoholic Fatty Liver Disease: The Emerging Burden in Cardiometabolic and Renal Diseases
    Eugene Han, Yong-ho Lee
    Diabetes & Metabolism Journal.2017; 41(6): 430.     CrossRef
Case Reports
Thyroid Dysfunction Associated with Administration of the Long-Acting Gonadotropin-Releasing Hormone Agonist
Eun Jin Han, Ha Do Song, Ji Hoon Yang, So Young Park, Sung Hoon Kim, Hyun Koo Yoon, Chang Hoon Yim
Endocrinol Metab. 2013;28(3):221-225.   Published online September 13, 2013
  • 3,862 View
  • 44 Download
  • 9 Citations
AbstractAbstract PDFPubReader   CrossRef-TDMCrossref - TDM

Gonadotropin-releasing hormone (GnRH) agonist has been used in the treatment of a wide variety of sex-hormone-related diseases, as the administration of GnRH agonist can alter the secretion of gonadotropin and sex hormones. Recently, we found that the long-acting GnRH agonist aggravated hyperthyroidism and induced painless thyroiditis. This is the first report to demonstrate the association of thyroid dysfunction with GnRH agonist injection in Korea. Here, we report three cases and emphasize the clinical importance of this aggravating factor in autoimmune thyroid disease.


Citations to this article as recorded by  
  • Thyroid Dysfunction after Gonadotropin-Releasing Hormone Agonist Administration in Women with Thyroid Autoimmunity
    Loris Marin, Guido Ambrosini, Marco Noventa, Flavia Filippi, Eugenio Ragazzi, Francesco Dessole, Giampiero Capobianco, Alessandra Andrisani, Alexander Schreiber
    International Journal of Endocrinology.2022; 2022: 1.     CrossRef
  • Effects of controlled ovarian stimulation on thyroid function during pregnancy
    Lingfei Li, Ling Li, Ping Li
    Biology of Reproduction.2022; 107(6): 1376.     CrossRef
  • Is gonadotropin-releasing hormone agonist usage really leading to thyroid dysfunction?
    Nafiye Yilmaz, Necati Hancerliogullari, Mustafa Kara, Yaprak Engin-Ustun
    Interventional Medicine and Applied Science.2020; 11(3): 136.     CrossRef
  • FANCA Polymorphism Is Associated with the Rate of Proliferation in Uterine Leiomyoma in Korea
    Eunyoung Ha, Seungmee Lee, So Min Lee, Jeeyeon Jung, Hyewon Chung, Eunsom Choi, Sun Young Kwon, Min Ho Cha, So-Jin Shin
    Journal of Personalized Medicine.2020; 10(4): 228.     CrossRef
  • Effects of controlled ovarian stimulation on thyroid stimulating hormone in infertile women
    Yuan-Jie Du, Xin Xin, Na Cui, Lei Jiang, Ai-Min Yang, Gui-Min Hao, Bu-Lang Gao
    European Journal of Obstetrics & Gynecology and Reproductive Biology.2019; 234: 207.     CrossRef
  • Myxedema Coma Following the Administration of Gonadotropin-releasing Hormone Agonist Complicated by Acute Pancreatitis
    Naoki Gocho, Ema Aoki, Chiho Okada, Takeshi Hirashima
    Internal Medicine.2018; 57(21): 3117.     CrossRef
  • The impact of thyroid autoimmunity on IVF/ICSI outcome: a systematic review and meta-analysis
    Andrea Busnelli, Alessio Paffoni, Luigi Fedele, Edgardo Somigliana
    Human Reproduction Update.2016; 22(6): 775.     CrossRef
  • The Potential Role of GnRH Agonists and Antagonists in Inducing Thyroid Physiopathological Changes During IVF
    Salvatore Gizzo, Marco Noventa, Michela Quaranta, Amerigo Vitagliano, Federica Esposito, Alessandra Andrisani, Roberta Venturella, Carlo Alviggi, Mario Plebani, Michele Gangemi, Giovanni Battista Nardelli, Donato D’Antona
    Reproductive Sciences.2016; 23(4): 515.     CrossRef
  • Brief Review of Articles in 'Endocrinology and Metabolism' in 2013
    Won-Young Lee
    Endocrinology and Metabolism.2014; 29(3): 251.     CrossRef
A Case of Hypothyroidism in Remission during Pregnancy.
Ha Do Song, Eun Jin Han, Sung Ja Lee, Ji Hoon Yang, So Young Park, Sung Hoon Kim, Ki Ok Han, Hyun Koo Yoon, Chang Hoon Yim
Endocrinol Metab. 2012;27(4):295-298.   Published online December 20, 2012
  • 1,857 View
  • 27 Download
AbstractAbstract PDF
Hypothyroidism should be treated in pregnancy, because it has been associated with an increased risk of adverse pregnancy complications, as well as detrimental effects upon fetal neurocognitive development. The goal of L-thyroxine (LT4) treatment is to normalize maternal serum TSH values within the trimester-specific pregnancy reference range. 50% to 85% of hypothyroid women being treated with exogenous LT4 need to increase the dose during pregnancy. In this study, we report a case of a 29-year-old woman with hypothyroidism who had been in remission and discontinued LT4 treatment during her pregnancy. Three months after delivery she had a relapse of hypothyroidism and was retreated with LT4. Many factors can influence the gestational requirement for LT4, therefore maternal serum TSH should be monitored and the LT4 dose should be adjusted in pregnant patients with treated hypothyroidism.
A Case Report of Hajdu-Cheney Syndrome.
Eun Jin Han, Jun Il Mun, So Yeon An, Yun Jung Jung, Ok Hwa Kim, Yoon Sok Chung
Endocrinol Metab. 2010;25(2):152-156.   Published online June 1, 2010
  • 1,690 View
  • 20 Download
  • 4 Citations
AbstractAbstract PDF
Hajdu-Cheney syndrome (HCS) is a rare skeletal dysplasia that is characterized by acroosteolysis of the distal phalanges, distinctive craniofacial and skull changes, dental abnormalities and generalized osteoporosis. The clinical and radiologic characteristics are variable and these characteristics progress with age. This syndrome shows autosomal dominant inheritance with sporadic cases. The genetic defects or molecular pathogenesis of HCS are still unknown. We experienced a case of Hajdu-Cheney syndrome in a 20-year-old man who had generalized osteoporosis with multiple non-traumatic spine compression fractures. He had acroosteolysis of the hands and feet, wormian bones in the skull, facial dysmorphism (mid-facial flattening, micrognathia and bushy eyebrows), a high arched palate, malocclusion and short dental alveolar processes. HCS was diagnosed based on the clinical and radiologic evidence. For the differential diagnosis, we excluded the other possible causes of the acroosteolysis and wormian bones, including hyperparathyroidism, osteogenesis imperfecta, hypophosphatemia and mandibuloacral dysplasia. The specific treatment of HCS is unknown, but case reports with bisphosphonate treatment have been reported.


Citations to this article as recorded by  
  • Band acro-osteolysis in a Black woman: a case report and review of the literature
    Jin-Myoung Dan, Cheungsoo Ha, Ho-Jae Lee
    Archives of Hand and Microsurgery.2022; 27(1): 62.     CrossRef
  • Clinical consequences in truncating mutations in exon 34 ofNOTCH2: Report of six patients with Hajdu-Cheney syndrome and a patient with serpentine fibula polycystic kidney syndrome
    Yoko Narumi, Byung-Joo Min, Kenji Shimizu, Itsuro Kazukawa, Kiyoko Sameshima, Koichi Nakamura, Tomoki Kosho, Yumie Rhee, Yoon-Sok Chung, Ok-Hwa Kim, Yoshimitsu Fukushima, Woong-Yang Park, Gen Nishimura
    American Journal of Medical Genetics Part A.2013; 161(3): 518.     CrossRef
  • An Unusual Presentation of Diabetic Ketoacidosis in Familial Hajdu-Cheney Syndrome: A Case Report
    Gil-Ho Lee, So-Yeon An, Young Bae Sohn, Seon-Yong Jeong, Yoon-Sok Chung
    Journal of Korean Medical Science.2013; 28(11): 1682.     CrossRef
  • Effect of Zoledronic Acid on Acro-Osteolysis and Osteoporosis in a Patient with Hajdu-Cheney Syndrome
    Sena Hwang, Dong Yoeb Shin, Seong Hwan Moon, Eun Jig Lee, Sung-Kil Lim, Ok Hwa Kim, Yumie Rhee
    Yonsei Medical Journal.2011; 52(3): 543.     CrossRef

Endocrinol Metab : Endocrinology and Metabolism